Swiss Parenterals Limited
Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $15.9M Total Trade · DGFT Verified
Swiss Parenterals Limited is an Indian pharmaceutical exporter with a total trade value of $15.9M across 18 products in 9 therapeutic categories. Based on 544 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ceftriaxone ($4.6M), Meropenem ($2.0M), Prednisolone ($1.5M).
Swiss Parenterals Limited — Export Portfolio & Destination Treemap
Who is Swiss Parenterals Limited? — Company Overview & Market Position
Swiss Parenterals Limited, incorporated on February 4, 1997, is a public unlisted company based in Ahmedabad, Gujarat, India. The company operates under the Corporate Identification Number (CIN) U85110GJ1997PLC031645. As of March 31, 2025, Swiss Parenterals reported a paid-up capital of ₹5.58 crore, with an authorized capital of ₹12 crore. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to both domestic and international markets.
In November 2025, Swiss Parenterals was acquired by Eris Lifesciences, a leading Indian pharmaceutical company. The acquisition was completed through a share swap, with Eris Lifesciences issuing 23,06,372 equity shares at ₹1,835.35 per share to Naishadh Shah, a director at Swiss Parenterals. This strategic move aimed to strengthen operational control and improve cost efficiencies within the group. (scanx.trade)
What Does Swiss Parenterals Limited Export? — Product Portfolio Analysis
Swiss Parenterals Limited Therapeutic Categories — 9 Specializations
Swiss Parenterals Limited operates across 9 therapeutic categories, with Advanced Antibiotics (61.0%), Corticosteroids (15.1%), Respiratory (9.3%) representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 67% of total exports.
Advanced Antibiotics
6 products · 61.0% · $9.7M
Corticosteroids
2 products · 15.1% · $2.4M
Respiratory
1 products · 9.3% · $1.5M
Antibiotics
2 products · 4.8% · $763.8K
CNS & Psychiatric
3 products · 3.4% · $542.1K
Ayurvedic & Herbal Products
1 products · 2.9% · $464.2K
Respiratory & OTC
1 products · 2.2% · $348.5K
Analgesics & Antipyretics
1 products · 0.9% · $150.0K
Cardiovascular
1 products · 0.3% · $46.2K
Product Portfolio — Top 18 by Export Value
Swiss Parenterals Limited exports 18 pharmaceutical products across 9 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Ceftriaxone | Advanced Antibiotics | $4.6M | 154 | 1.6% | 14 |
| 2 | Meropenem | Advanced Antibiotics | $2.0M | 46 | 0.9% | 10 |
| 3 | Prednisolone | Respiratory | $1.5M | 46 | 1.5% | 14 |
| 4 | Fosfomycin | Advanced Antibiotics | $1.4M | 27 | 10.5% | 2 |
| 5 | Methylprednisolone | Corticosteroids | $1.3M | 36 | 4.5% | 5 |
| 6 | Hydrocortisone | Corticosteroids | $1.1M | 50 | 1.7% | 14 |
| 7 | Piperacillin | Advanced Antibiotics | $1.0M | 21 | 1.2% | 9 |
| 8 | Vancomycin | Antibiotics | $717.0K | 47 | 0.8% | 15 |
| 9 | Taila | Ayurvedic & Herbal Products | $464.2K | 15 | 6.1% | 3 |
| 10 | Imipenem | Advanced Antibiotics | $450.0K | 9 | 1.3% | 3 |
| 11 | Diazepam | CNS & Psychiatric | $365.7K | 27 | 4.9% | 5 |
| 12 | Ephedrine | Respiratory & OTC | $348.5K | 14 | 1.5% | 13 |
| 13 | Amikacin | Advanced Antibiotics | $318.5K | 26 | 1.5% | 11 |
| 14 | Morphine | Analgesics & Antipyretics | $150.0K | 3 | 0.8% | 5 |
| 15 | Alprazolam | CNS & Psychiatric | $109.7K | 4 | 0.7% | 11 |
| 16 | Clonazepam | CNS & Psychiatric | $66.7K | 6 | 0.1% | 10 |
| 17 | Streptomycin | Antibiotics | $46.8K | 5 | 8.2% | 4 |
| 18 | Digoxin | Cardiovascular | $46.2K | 8 | 2.1% | 7 |
Swiss Parenterals Limited exports 18 pharmaceutical products across 9 therapeutic categories with a total export value of $15.9M. The top category is Advanced Antibiotics (61.0% of portfolio), followed by Corticosteroids (15.1%), indicating a concentrated portfolio with the top 5 products accounting for 67.2% of total export value.
Key Metrics
Top Categories
Top Export Routes
Related Analysis
Need Detailed Data?
Shipment-level records, pricing & buyer contacts for Swiss Parenterals Limited.
Request DemoSwiss Parenterals Limited — Corporate Profile & Information
Headquarters, ownership, manufacturing facilities, and key leadership
1Corporate Overview
Swiss Parenterals Limited, incorporated on February 4, 1997, is a public unlisted company based in Ahmedabad, Gujarat, India. The company operates under the Corporate Identification Number (CIN) U85110GJ1997PLC031645. As of March 31, 2025, Swiss Parenterals reported a paid-up capital of ₹5.58 crore, with an authorized capital of ₹12 crore. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to both domestic and international markets.
In November 2025, Swiss Parenterals was acquired by Eris Lifesciences, a leading Indian pharmaceutical company. The acquisition was completed through a share swap, with Eris Lifesciences issuing 23,06,372 equity shares at ₹1,835.35 per share to Naishadh Shah, a director at Swiss Parenterals. This strategic move aimed to strengthen operational control and improve cost efficiencies within the group. (scanx.trade)
2Manufacturing Facilities
Swiss Parenterals operates two cGMP-compliant manufacturing facilities in India, specializing in the production of both sterile and oral solid dosage forms. These facilities adhere to stringent international quality standards, ensuring the production of high-quality pharmaceutical products. The company's product line includes a wide range of formulations, such as tablets, capsules, syrups, and injections, catering to various therapeutic categories.
3Key Leadership
The leadership team at Swiss Parenterals comprises several key individuals:
- Naishadh Vikrambhai Shah: Whole-Time Director, appointed on May 1, 2007.
- Piyush Sumantlal Thakkar: Chief Financial Officer, appointed on December 31, 2016.
- Krishnakumar Vaidyanathan: Director, appointed on February 15, 2024.
- Kaushal Kamlesh Shah: Director, appointed on February 15, 2024.
- Sachin Shah: Director, appointed on February 15, 2024.
Where Does Swiss Parenterals Limited Export? — Destination Intelligence
Regulated market presence, emerging market penetration, and geographic strategy
1Regulated Markets
Swiss Parenterals has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals from multiple global regulatory agencies, such as EU GMP, PIC/S, ANVISA, and INVIMA, facilitating its market access in these regions. Additionally, Swiss Parenterals exports its products to over 50 countries, indicating a broad international footprint.
2Emerging Markets
Swiss Parenterals has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, as evidenced by certifications like EU GMP and ANVISA, has enabled it to penetrate these markets effectively. The acquisition by Eris Lifesciences in January 2026 is expected to further enhance Swiss Parenterals' capabilities and market presence in these regions. (scanx.trade)
3Geographic Strategy
Swiss Parenterals has strategically diversified its geographic presence, exporting products to over 50 countries. This diversification mitigates concentration risk and positions the company to leverage growth opportunities in various global markets. The acquisition by Eris Lifesciences in January 2026 is anticipated to strengthen Swiss Parenterals' strategic direction, enhancing its operational control and market reach. (scanx.trade)
Swiss Parenterals Limited — Manufacturing & Regulatory Profile
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
1FDA Status
Swiss Parenterals has achieved significant milestones in the U.S. market, including FDA facility registrations and approved Abbreviated New Drug Applications (ANDAs). The company's adherence to cGMP standards and international quality certifications has facilitated its entry into the U.S. market. The acquisition by Eris Lifesciences in January 2026 is expected to further bolster Swiss Parenterals' capabilities and market presence in the U.S. (scanx.trade)
2WHO & EU GMP
Swiss Parenterals holds certifications from the World Health Organization (WHO) and the European Union Good Manufacturing Practice (EU GMP), ensuring compliance with international manufacturing standards. These certifications have enabled the company to export its products to over 50 countries, including those in the European Union. The acquisition by Eris Lifesciences in January 2026 is expected to enhance Swiss Parenterals' manufacturing capabilities and compliance with global standards. (scanx.trade)
3CDSCO & Indian Regulatory
Swiss Parenterals operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian regulatory requirements. The acquisition by Eris Lifesciences in January 2026 is anticipated to strengthen Swiss Parenterals' compliance and operational capabilities within the Indian regulatory landscape. (scanx.trade)
4Recent Regulatory Actions
As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Swiss Parenterals. The company's adherence to cGMP standards and international quality certifications suggests a strong compliance record. The acquisition by Eris Lifesciences in January 2026 is expected to further enhance Swiss Parenterals' compliance and operational standards. (scanx.trade)
Swiss Parenterals Limited — Competitive Positioning Among Indian Pharma Exporters
Market share comparison, key differentiators, and strategic analysis
1Competitive Landscape
Swiss Parenterals operates in a competitive landscape, with several key players in the pharmaceutical manufacturing sector. The company's focus on generic and specialty pharmaceutical products, along with its adherence to international quality standards, positions it favorably in the market. The acquisition by Eris Lifesciences in January 2026 is expected to strengthen Swiss Parenterals' competitive position through enhanced operational control and market reach. (scanx.trade)
2Key Differentiators
Swiss Parenterals' key differentiators include its extensive experience in manufacturing both prescription and over-the-counter drugs, dietary supplements, and cosmetics. The company's adherence to cGMP standards and international quality certifications, such as EU GMP and ANVISA, underscores its commitment to quality. The acquisition by Eris Lifesciences in January 2026 is expected to further enhance Swiss Parenterals' capabilities and market presence.
3Strategic Position
Swiss Parenterals has strategically positioned itself as a leading manufacturer of generic and specialty pharmaceutical products, with a diverse portfolio that includes sterile injectables, oral solids, and complex formulations. The company's expansion into veterinary and nutraceutical products highlights its commitment to growth in various markets. The acquisition by Eris Lifesciences in January 2026 is expected to strengthen Swiss Parenterals' strategic direction, enhancing its operational control and market reach.
Buyer Due Diligence Brief — Evaluating Swiss Parenterals Limited as a Supplier
Track record assessment, certifications to verify, and pre-order checks
1Supplier Assessment
Swiss Parenterals has demonstrated a strong track record in pharmaceutical manufacturing, with a diverse product portfolio and a significant presence in over 50 countries. The company's adherence to cGMP standards and international quality certifications, such as EU GMP and ANVISA, underscores its reliability as a supplier. The acquisition by Eris Lifesciences in January 2026 is expected to further enhance Swiss Parenterals' operational capabilities and reliability. (scanx.trade)
2Certifications to Verify
Importers should verify the following certifications when considering Swiss Parenterals as a supplier:
- FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.
- WHO-GMP Certification: Ensure compliance with World Health Organization Good Manufacturing Practice standards.
- EU GMP Certification: Verify adherence to European Union Good Manufacturing Practice standards.
- ISO Certification: Check for compliance with International Organization for Standardization standards.
These certifications can typically be verified through the respective regulatory agencies' official websites or by contacting Swiss Parenter
Frequently Asked Questions — Swiss Parenterals Limited
How many pharmaceutical products does Swiss Parenterals Limited export from India?
Swiss Parenterals Limited exports 18 pharmaceutical products across 9 therapeutic categories. The top exports are Ceftriaxone ($4.6M), Meropenem ($2.0M), Prednisolone ($1.5M), Fosfomycin ($1.4M), Methylprednisolone ($1.3M). Total export value is $15.9M.
What is Swiss Parenterals Limited's total pharmaceutical export value?
Swiss Parenterals Limited's total pharmaceutical export value is $15.9M, based on 544 verified shipments recorded in Indian Customs (DGFT) data.
What therapeutic categories does Swiss Parenterals Limited cover?
Swiss Parenterals Limited exports across 9 therapeutic categories. The largest are Advanced Antibiotics (61.0%, 6 products), Corticosteroids (15.1%, 2 products), Respiratory (9.3%, 1 products).
Get Full Swiss Parenterals Limited Export Intelligence
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Official References & Regulatory Resources
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Matching: Swiss Parenterals Limited identified across shipments using name normalization.
- 2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 3.Market Share: Calculated per product as Swiss Parenterals Limited's capped value divided by total Indian exports for that product.
- 4.Shipment Count: Based on 544 individual customs records matching Swiss Parenterals Limited.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
18 Products Tracked
9 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Data Source & Methodology
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.